GlassScriptPhysician profile
Dara D Spearman
NPI 1588783419
$9,254.74
in general payments reported to CMS, 2019-2025
27 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $775 · 2021: $904 · 2022: $652 · 2023: $3,623 · 2024: $1,104 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019 · Consulting Fee: $2,625 · Education: $279 · Travel and Lodging: $56.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,019.40 |
| Consulting Fee | $2,625.00 |
| Education | $279.46 |
| Travel and Lodging | $56.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,414.67 | 2019-2025 | Sotyktu |
| Abbvie INC. | $1,395.74 | 2019-2025 | Rinvoq |
| Galderma Laboratories, L.P. | $844.15 | 2019-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $523.19 | 2019-2025 | |
| Janssen Biotech, INC. | $447.58 | 2020-2025 | Tremfya |
| Ucb, INC. | $406.78 | 2023-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $404.03 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $377.59 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $264.63 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $217.64 | 2019-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $181.73 | 2023 | |
| Merck Sharp & Dohme LLC | $156.65 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $97.56 | 2022-2025 | |
| Incyte Corporation | $84.15 | 2023-2024 | Opzelura |
| Amgen INC. | $64.73 | 2021-2023 | Otezla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $58.78 | 2019-2023 | Targretin |
| Leo Pharma INC. | $52.45 | 2025 | Anzupgo |
| Dermavant Sciences, INC. | $44.25 | 2024 | Vtama |
| Journey Medical Corporation | $42.01 | 2021 | |
| Organogenesis INC. | $39.84 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.24 | 2019 | |
| Strata Skin Sciences, INC. | $24.81 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $19.71 | 2024 | Acthar |
| Amag Pharmaceuticals, INC. | $18.11 | 2020 | |
| Organon LLC | $15.69 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $15.62 | 2020 | |
| Exelixis INC. | $13.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dara Spearman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.